Serotonin 5-HT 2A receptors (5-HT 2A Rs) have been implicated in schizophrenia. However, postmortem studies on 5-HT 2A Rs expression and functionality in schizophrenia are scarce. The 5-HT 2A R mRNA and immunoreactive protein expression were evaluated in postmortem tissue from dorsolateral prefrontal cortex (DLPFC) of antipsychotic-free ( n = 18) and antipsychotictreated ( n = 9) subjects with schizophrenia, and matched controls ( n = 27). Functional coupling of 5-HT 2A R to G-proteins was tested by measuring the activation induced by the agonist ( ±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (( ±)DOI) in antibody-capture [ 35 S]GTP γ S scintillation proximity assays (SPA). In antipsychotic-free schizophrenia subjects, 5-HT 2A R mRNA expression and protein immunoreactivity in total homogenates was similar to controls. In contrast, in antipsychotic-treated schizophrenia subjects, lower mRNA * Please cite this article as: A. García-Bea, P. Miranda-Azpiazu and C. Muguruza et al., Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via G αi1-proteins, European Neuropsychopharmacology, https://doi. JID: NEUPSY [m6+;4:28 ] expression (60 ±9% vs controls) and a trend to reduced protein immunoreactivity (86 ±5% vs antipsychotic-free subjects) just in membrane-enriched fractions was observed. [ 35 S]GTP γ S SPA revealed a significant ˜6% higher stimulation of G αi1 -protein by ( ±)DOI in schizophrenia, whereas activation of the canonical G αq/11 -protein pathway by ( ±)DOI remained unchanged. Expression of G αi1 -and G αq/11 -proteins did not differ between groups. Accordingly, in rats chronically treated with clozapine, but not with haloperidol, a 30-40% reduction was observed in 5-HT 2A R mRNA expression, 5-HT 2A R protein immunoreactivity and [ 3 H]ketanserin binding in brain cortical membranes. Overall, the data suggest a supersensitive 5-HT 2A R signaling through inhibitory G αi1 -proteins in schizophrenia. Together with previous results, a dysfunctional pro-hallucinogenic agonist-sensitive 5-HT 2A R conformation in postmortem DLPFC of subjects with schizophrenia is proposed. Atypical antipsychotic treatment would contribute to counterbalance this 5-HT 2A R supersensitivity by reducing receptor expression.
Introduction
Several findings support the involvement of the serotonin 5-HT 2A receptors (5-HT 2A Rs) in schizophrenia. Hallucinogenic drugs, such as psilocybin or lysergic acid diethylamide (LSD), trigger mental states resembling schizophrenia in healthy humans through the activation of 5-HT 2A Rs ( Carhart-Harris et al., 2016 ; Geyer and Vollenweider, 2008 ; Nichols, 2016 ; Preller et al., 2018 ; Quednow et al., 2012 ; Schmid et al., 2015 ) , and worsen psychosis in schizophrenia patients ( Hoch et al., 1952 ) . Most of the atypical antipsychotic drugs are characterized by high potency as 5-HT 2A R antagonists ( Meltzer and Massey, 2011 ; Miyamoto et al., 2012 ) . 5-HT 2A R knockout (KO) mice are insensitive to the behavioral effects of serotonergic psychedelics ( González-Maeso et al., 2003 , and genetic evidence links polymorphisms in the 5-HT 2A R ( HTR2A ) gene with sensorimotor gating deficits in schizophrenia ( Geyer and Vollenweider, 2008 ) . Moreover, a differential epigenetic methylation of the HTR2A gene in the brain of subjects with schizophrenia has been described ( Cheah et al., 2017 ; Abdolmaleky et al., 2011 ) . In addition, studies in immunological, pharmacological, congenital and genetic rodent models of schizophrenia have demonstrated increased 5-HT 2A R expression ( Dean et al., 2008b ; Fomsgaard et al., 2018 ; Holloway et al., 2013 ; Malkova et al., al.,2014 ; Moreno et al., 2011 ) and/or functionality Malkova et al., 2014 ; Moreno et al., 2011 ; Santini et al., 2013 ) . Together, these findings suggest that up-regulation of cortical 5-HT 2A Rs could predispose to psychosis in schizophrenia.
The status of brain 5-HT 2A Rs in schizophrenia has been mainly evaluated with radiotracers, both by in vivo neuroimaging and in vitro radioligand binding techniques, raising different outcomes. Thus, while some postmortem studies support increased 5-HT 2A R density, others observed no changes and even decreases (see for reviews, Dean, 2003 ; González-Maeso and Sealfon, 2009 ; Selvaraj et al., 2014 ) . These apparent discrepancies may depend on several confounding issues, such as the pharmacological properties of the radioligands used to bind 5-HT 2A Rs, tissue preparation (total homogenates, membranes, cytosol, tissue sections), discrimination between antipsychotic-free and antipsychotic-treated subjects, the brain area selected, and other demographic and methodological variables (age, postmortem delay, gender, etc. ) . Immunodetection is a feasible method for in vitro postmortem studies of neurotransmitter receptors. The use of antibodies to quantify receptor protein expression minimizes concerns of pharmacological selectivity associated with radioligands and avoids the influence of residual antipsychotic presence in samples competing for the receptor. However, protein immunodetection fails to keep intact the ternary structure and does not discriminate between molecular states of the receptor. In this context, only one study of 5-HT 2A R immunoreactivity in schizophrenia restricted to cerebellum evaluation has been reported ( Eastwood et al., 2001 ) . Similarly, studies with positron emission tomography (PET) in living humans have shown controversial results although the potential binding seems to be reduced when selective 5-HT 2A R radiotracers as [ 18 F]altanserin are used (see review in Selvaraj et al., 2014 ; Erritzoe et al., 2008 ; Rasmussen et al., 2010 Rasmussen et al., , 2016 .
The canonical 5-HT 2A R signaling pathway involves activation of G αq/11 -proteins that, subsequently, activate phospholipase C, leading to inositol 1,4,5-triphosphate and 1,2diacylglycerol accumulation, releasing Ca + 2 from intracellular stores and activating protein kinase C. In heterologous expression systems and rodents, non-hallucinogenic LSD-analogous 5-HT 2A R agonists, such as lisuride, exclusively activate G αq/11 -proteins, whereas hallucinogenic 5-HT 2A R agonists, such as LSD and ( ±)DOI, engage signaling through G αq/11 -but also through inhibitory G αi/o -proteins ( González-Maeso et al., 2007 ; Ibarra-Lecue et al., 2018 ; Karaki et al., 2014 ) . This differential activation is compatible with the presence of a "functional selectivity" (also known as "agonist-directed trafficking of receptor signaling" or "biased agonism") phenomenon in 5-HT 2A R activation ( Urban et al., 2007 ) . Despite the extensive evaluation of brain 5-HT 2A Rs density in schizophrenia, the status of their functional coupling to G-proteins remains unknown. Moreover, the hypothesis that a dysregulation of 5-HT 2A Rs in schizophrenia could selectively affect the receptor coupling to the hallucinogenic-mediated G αi/o -protein signaling has not been investigated.
The present study evaluated 5-HT 2A R mRNA and protein expression in postmortem dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and controls. A strict treatment-controlled design was used to verify the Please cite this article as: A. García-Bea, P. Miranda-Azpiazu and C. Muguruza et al., Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via G αi1-proteins, European Neuropsychopharmacology, https://doi.org/10.1016/j.euroneuro.2019.10.013 JID: NEUPSY [m6+; 4:28 ] influence of antipsychotic drug treatment. Moreover, the existence of dysfunctions in the coupling of 5-HT 2A R to different G-protein-mediated pathways between schizophrenia and control subjects was also tested. The DLPFC was selected as region of interest based on the described morphological alterations associated to schizophrenia ( Jarskog et al., 2007 ; Lewis and González-Burgos, 2008 ) and previous findings in PET studies ( Rasmussen et al., 2010 ( Rasmussen et al., , 2016 .
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Experimental procedures
Human brain samples
Human brains were obtained at autopsies in the Basque Institute of Legal Medicine, Bilbao, Spain, in compliance with policies of research and ethical boards for postmortem studies. Deaths were subjected to retrospective searching for diagnosis and treatment using examiner ś information and medical records. Twenty-seven subjects with antemortem diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, DSM-IV-TR) were selected and matched to 27 control subjects without neuropsychiatric or drug abuse disorders. Individual matching was performed for age, gender and, as much as possible, postmortem delay (PMD). A toxicological screening performed at the National Institute of Toxicology, Madrid, Spain, allowed the classification of subjects with schizophrenia as "antipsychoticfree" (AP-free, n = 18) or "antipsychotic-treated" (AP-treated, n = 9) according to the absence or presence of antipsychotic drugs in blood at the moment of death. It is noteworthy to remark that all the current AP-free subjects had received antipsychotic prescription and should not be considered never-treated naïve subjects. Specimens of DLPFC were dissected following standard procedures ( Rajkowska and Goldman-Rakic, 1995 ) and stored at −80 °C. A full description of the AP-free, AP-treated subjects, and respective controls with tissue integrity information (PMD, storage time, RNA integrity number, brain pH) is shown in Supplementary Table S1.
Animals and treatments
Male Sprague-Dawley rats (220-320 g) were housed on a 12 h light/dark cycle at room temperature (22 °C) and 60% humidity with food and water available ad libitum . Animals were obtained and kept at the Animal Facility SGIker of the University of the Basque Country. Animal care and experimental protocols were in accordance with European Union regulations and were approved by the UPV/EHU institutional Ethics Committee for animal welfare (CEEA). Rats were injected i.p., every 12 h, during 21 days, with saline (1 ml/kg, n = 10), haloperidol (0.5 mg/kg, n = 10) (Sigma Aldrich, MO, USA) or clozapine (5 mg/kg, n = 10) (Tocris, Bristol, UK). Haloperidol and clozapine were selected as representative drugs with typical (selective affinity for dopamine D 2 receptor vs 5-HT 2A R) or atypical (higher affinity for 5-HT 2A R than dopamine D 2 receptor family) antipsychotic profile, respectively. Animals were sacrificed 48 h after the last injection of clozapine and 72 h after the last injection of haloperidol or saline. Brains were removed and the cortex was dissected and stored at −80 °C.
Quantitative real-time reverse transcription polymerase chain reaction
Sample preparation and procedures for determination of mRNA expression of genes encoding 5-HT 2A ( HTR2A, Htr2a) and 5-HT 2C ( HTR2C, Htr2c) receptors by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) were conducted by using published procedures ( Muguruza et al., 2014 ) . mRNA expression was normalized using the endogenous housekeeping genes glyceraldehyde 3-phosphate dehydrogenase ( GAPDH ), beta-actin ( ACTB ) and ribosomal protein S13 ( RPS13 ) for human samples, and Gapdh, Actb and ribosomal protein S29 ( Rps29 ) for rat samples. A negative internal control and a reference sample (pool of controls) for each assay were included in all PCR plates. The assays identification numbers and conditions of the qRT-PCR are described in Supplementary Tables S2 and S3 , respectively. Human samples were also assayed for RNA integrity number (RIN) using the Agilent 2100 Bioanalyzer (Agilent Technologies) ( Stan et al., 2006 ) .
Immunodetection
Western blot experiments were performed in total homogenates ( García-Fuster et al., 2008 ) , and in membrane-enriched (P 2 ) fractions ( Muguruza et al., 2013 ) as previously described. The selected primary antibodies were rabbit polyclonal anti-5-HT 2A R (ab16028; 1:2000) from Abcam (Cambridge, UK), mouse monoclonal anti-5-HT 2A R (sc-166775; 1:20,000), mouse monoclonal anti-G αi1 -(sc-56536; 1:100) and rabbit polyclonal anti-G αq/11 -proteins (sc-392; 1:300) from Santa Cruz (CA, USA), and mouse monoclonal anti-βactin (A1978; 1:200,000) from Sigma Aldrich, as loading control. The fluorescent conjugated secondary antibodies Alexa Fluor TM 680 goat anti-rabbit (A21076; 1:2500-1:8000) and Alexa Fluor TM 680 goat anti-mouse (A21057; 1:8000) from Invitrogen (OR, USA), and IRDye TM 800 donkey anti-mouse (610-732-002; 1:10,000) and IRDye TM 800 goat anti-rabbit (611-132-002; 1:5000) from Rockland Immunochemicals (PA, USA), were used to detect and quantify the immunoreactive signal by using the Odyssey Infrared Imaging System (LI-COR Biosciences, NE, USA). All samples were analyzed at least two times in different gels, obtaining a minimum of four measurements for each sample.
Antibody-capture [ 35 S]GTP γS scintillation proximity assay (SPA)
Specific activation of the different G α -proteins was determined by using a [ 35 S]GTP γ S binding assay followed by incubation with specific antibodies (see above) and SPA beads, as described ( Diez-Alarcia et al., 2016 ; Erdozain et al., 2012 ) . The 5-HT 2A/C R agonist ( ±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (( ±)DOI) (Sigma Aldrich) was used to stimulate [ 35 S]GTP γ S (1250 Ci/mmol) (Perkin Elmer Life Sciences, Maanstraat, Germany) binding at two concentrations close to those that elicit the 50% (EC 50 ≈300 nM) and the maximal (10 μM) effects, estimated from concentration-effect curves (data not shown). The 5-HT 2A R antagonist ketanserin (10 μM) (Tocris, UK) was used to determine the 5-HT 2A R specific component of the stimulation induced by ( ±)DOI. Preliminary results demonstrated that G αi1 displays, among the inhibitory G αi/o -proteins, the most efficient response of [ 35 S]GTP γ S binding stimulation by ( ±)DOI ( Miranda-Azpiazu et al., 2013 ).
Radioligand binding
Saturation binding assays (0.03-9 nM, ten concentrations) with [ 3 H]ketanserin (specific activity 67 Ci/mmol; Perkin Elmer) in rat brain cortex membrane fractions were performed as described ( Muguruza et al., 2013 ( Muguruza et al., , 2014 . At this concentration range, JID: NEUPSY [m6+; 4:28 ] 
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Data analysis and statistical procedures
All studies were performed under a paired design where each schizophrenia case and the respective matched control were always processed simultaneously. The qRT-PCR data analysis was performed by StepOne Software v2.1 (Applied Biosystems TM ). The relative mRNA amount was calculated as 2 − Ct ±SEM -normalized by both housekeeping genes and reference sample expression -and data were standardized to control samples. In Western blot assays, the immunoreactivity value of the target proteins was corrected by the corresponding value of β-actin; and then, calculated as percentage of a standard sample loaded in every single gel to control for inter-assay variability. Finally, data were standardized considering the mean value of the control samples as 100%. In radioligand binding experiments, the apparent equilibrium dissociation constant ( K D ) and the maximum density of specific binding sites ( B max ) were obtained. Specific binding data obtained from antibody-capture [ 35 S]GTP γ S SPA were transformed to percentage of basal binding value (binding in the absence of any exogenous drug) for each G α -protein subtype. Statistical comparisons were made by Student's t -test and oneway analysis of variance (ANOVA) followed by Dunnett's post-hoc test. Potential association of experimental results with age, PMD, RIN, storage time and pH were tested. If significant correlation existed, the interaction was explored by analysis of covariance (AN-COVA) where the group (schizophrenia or control) was the independent variable, age, PMD, RIN, storage time or pH were the covariates, and the experimental result was the dependent variable. Statistical comparisons of non-linear analyses in radioligand binding assays were conducted by F -test.
The analyses were carried out by using GraphPad Prism 5 TM and InVivo Stat TM softwares. Values are shown as mean ±SEM. The level of significance was chosen as p < 0.05.
Results
HTR2A mRNA expression and protein immunoreactivity in postmortem brain of subjects with schizophrenia and matched controls
The mRNA expression of HTR2A showed no difference between subjects with schizophrenia and controls ( Fig.  1 (a) ). However, when subjects were grouped depending on the absence/presence of antipsychotics in blood, lower HTR2A mRNA expression was observed in AP-treated group (60 ±9% % vs matched controls, p < 0.05), but not in AP-free group (110 ±9% vs matched controls) ( Fig. 1 (a) ). As HTR2A mRNA expression showed significant correlation with the RIN value ( r = 0.43, p < 0.01), results were reanalyzed by ANCOVA with RIN as covariate. This analysis further confirmed the significant decrease of HTR2A mRNA expression in AP-treated subjects ( F [1,15] = = 18.72, p < 0.05). The mRNA expression of HTR2C was determined in parallel as negative control. When compared to respective controls, HTR2C mRNA expression was unaltered in both AP-free and AP-treated subjects ( Fig. 1 (b) ).
In order to quantify the protein expression of 5-HT 2A R, immunodetection with a specific antibody was performed. Western blot assays showed a single band at ˜55 kDa (Supplementary Fig. S1 ) whose specificity has previously been demonstrated in 5-HT 2A R KO mice ( Fribourg et al., 2011 ) . The 5-HT 2A R protein immunoreactivity in total brain homogenates showed no significant alteration in schizophre-nia ( Fig. 1 (c) ), even when subjects with schizophrenia were separated in AP-free and AP-treated groups ( Fig. 1 (c) ). This lack of modulation contrasts with the elevated 5-HT 2A R density previously observed by radioligand binding assays in brain membrane fractions of AP-free subjects ( Muguruza et al., 2013 ) . In order to check whether methodological issues could underlie this inconsistency (radioligand binding vs immunodetection, and use of total homogenates vs membrane-enriched fractions), new Western blot experiments were performed in membrane preparations from DLPFC of the same subjects. No clear differences were observed in membrane 5-HT 2A R immunoreactivity between schizophrenia and corresponding matched controls neither in the AP-free group nor in the AP-treated group. However, although not in statistically significant way, immunoreactive signal of 5-HT 2A Rs in P 2 -membrane preparations was 17 ±6% lower in AP-treated than in AP-free subjects ( Fig. 1 (d) ).
Functional coupling of 5-HT 2A Rs to G αq/11 -and G αi1 -proteins in postmortem brain of subjects with schizophrenia and matched controls
Experiments of 5-HT 2A R agonist-mediated stimulation of [ 35 S]GTP γ S binding to different G α -protein subtypes were performed in DLPFC membranes to test the different 5-HT 2A R signaling patterns. This approach informs about the functional status of 5-HT 2A Rs in postmortem brain and allows the evaluation of alterations in schizophrenia.
The 5-HT 2A/C R agonist ( ±)DOI (300 nM and 10 μM) produced a selective activation of G αq/11 -and G αi1 -proteins ( Fig. 2 (a) and (b)) but not of G αi2, G αo and G αs subtypes (Supplementary Fig. S2 ). The activation of these G α -proteins was antagonized by the selective 5-HT 2A R antagonist ketanserin (10 μM) ( Fig. 2 (a) and (b) ). Moreover, the stimulation of [ 35 S]GTP γ S binding by ( ±)DOI was absent in cortex of 5-HT 2A R KO mice ( Supplementary Fig. S3 ). ( ±)DOI stimulatory effects did not correlate with any of the potential confounding factors (age, PMD, RIN, storage time, pH and basal binding values).
In membrane fractions, basal binding of [ 35 S]GTP γ S to G αq/11 -and G αi1 -proteins, before ( ±)DOI stimulation, was not different between schizophrenia subjects (45 ±4 fmol/ μg protein for G αq/11 ; 41 ±4 fmol/ μg protein for G αi1 ) and controls (37 ±4 fmol/ μg protein for G αq/11 ; 38 ±3 fmol/ μg protein for G αi1 ).
The stimulation of G αq/11 -protein induced by ( ±)DOI showed no significant differences between schizophrenia and control groups ( Fig. 2 (a) ), even when considering the presence of antipsychotic treatment. By contrast, G αi1protein stimulation induced by ( ±)DOI at the two concentrations tested was significantly higher in the whole group of schizophrenia (˜5-6% increase; p < 0.05) compared to controls ( Fig. 2 (b) ). This pattern of higher G αi1 -protein stimulation was slightly more robust in AP-free subjects (˜6-7% increase vs matched controls) than in AP-treated subjects (˜5% increase vs matched controls). Therefore, the canonical G αq/11 -protein pathway of 5-HT 2A Rs was unaltered whereas the "pro-hallucinogenic" G αi1 -protein pathway was functionally overactive in DLPFC of subjects with schizophrenia. JID: NEUPSY [m6+; 4:28 ] In order to test whether the supersensitivity of the ( ±)DOI stimulation of [ 35 S]GTP γ S binding may lay directly on 5-HT 2A Rs or on enhanced G αi1 -protein density, expression experiments of G αq/11 -and G αi1 -protein subtypes were performed in membrane fractions of DLPFC samples from the same subjects. No significant differences were observed between schizophrenia and control groups in the immunoreactivity neither of G αq/11 -(100 ±4% vs matched controls, p > 0.05) nor of G αi1 -proteins (89 ±5% vs matched controls, p > 0.05) ( Fig. 2 (c) and (d) ), independently of the absence/presence of antipsychotic treatment ( Fig. 2 (c) and (d)).
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Effects of chronic treatment with antipsychotics on Htr2a and Htr2c mRNA expression, 5-HT 2A R immunoreactivity and [ 3 H]ketanserin binding in rat brain cortex
Taking into account the results obtained in human DLPFC of subjects with schizophrenia, the effects of chronic (21 days) treatment with two different antipsychotic drugs (haloperidol and clozapine) on Htr2a and Htr2c mRNA expression and 5-HT 2A R protein immunoreactivity were tested in rat brain cortex.
Htr2a mRNA expression was lower in rats after chronic treatment with the atypical antipsychotic clozapine (70 ±5% vs saline, p < 0.01), but not with the typical antipsychotic haloperidol ( Fig. 3 (a) ). In contrast, Htr2c mRNA expression did not vary among the different groups ( Fig. 3 (b) ).
The 5-HT 2A R protein immunoreactivity in total homogenates from rat cortex revealed no changes in the different experimental groups ( Fig. 3 (c) ). By contrast, in P 2membrane preparations from the same animals, decreased 5-HT 2A R immunoreactivity was observed in clozapinetreated rats (63 ±6% vs saline, p < 0.01) with absence of changes in haloperidol-treated animals ( Fig. 3 (d) ).
In order to confirm the down-regulation observed in rat brain cortical membranes by immunoblotting assays, saturation binding experiments with [ 3 H]ketanserin were performed in the same membrane preparations. In this case, a significant decrease of 5-HT 2A R density was also observed in clozapine-treated ( B max 64 ±4% vs saline; p < 0.01) but not in haloperidol-treated rats. No significant differences were observed in K D values for any experimental group ( Fig. 3 (e) ; Table S4 ).
Discussion
The present study shows that density of 5-HT 2A Rs in DLPFC of subjects with schizophrenia is not altered when evaluated by protein immunodetection. This finding apparently contrasts with previous results in a similar population showing that [ 3 H]ketanserin binding to 5-HT 2A Rs was increased in AP-free and returned to control values JID: NEUPSY [m6+; 4:28 ] in AP-treated subjects ( Gonzalez-Maeso et al., 2008 ; Muguruza et al., 2013 ) . Likewise, evidence is provided that mRNA expression of HTR2A is unaltered in DLPFC of AP-free subjects. On the other hand, the study reports, for the first time, that the hallucinogenic agonist ( ±)DOI displays a supersensitive coupling of 5-HT 2A R to the G αi1 -protein pathway in schizophrenia, while no alterations in the canonical G αq/11 -protein pathway are detected. Altogether, the findings in the present and previous studies ( Muguruza et al., 2013 ) prompt the hypothesis of an enhanced proportion of agonist-sensitive 5-HT 2A Rs in DLPFC of AP-free schizophrenia subjects. This increased 5-HT 2A R sensitivity would not be the consequence of increased receptor synthesis and expression, but seems to represent an altered conformational exchange between G-protein-coupled (active) and G-protein-uncoupled receptor states ( Muguruza et al., 2013 ) . The equilibrium displacement towards the agonistsensitive active conformation of the 5-HT 2A R constitutes the signal-driving stimulus that is experimentally observed as an increased coupling activity to G-proteins in schizophrenia. This 5-HT 2A R supersensitivity occurs without changes in basal [ 35 S]GTP γ S binding values or G α -protein immunoreactive levels, which discards a primary alteration of G-protein density. Whether this trend to 5-HT 2A Rs hyperactivity represents an intrinsic constitutive dysfunction of the receptor or is a consequence of abnormalities in associated proteins ( Dean et al., 2008a ; Roth, 2011 ) deserves further investigation. Despite the multiple mRNA expression and radioligand binding studies performed in postmortem brain, a definitive understanding of 5-HT 2A R status in schizophrenia, especially in the absence of antipsychotic treatment, remains uncertain. Thus, postmortem radioligand binding assays have found decreased, unchanged and increased brain 5-HT 2A R density in schizophrenia (see for references, Dean, 2003 ; González-Maeso and Sealfon, 2009 ) . In vivo PET neuroimaging studies have mainly proposed a reduction of the 5-HT 2A R binding potential in AP-free patients (see for references, Selvaraj et al., 2014 ; Rasmussen et al., 2010 Rasmussen et al., , 2016 . As already mentioned, these apparent discrepancies might be related to the different pharmacological profile of the radiolabeled drugs used as radiotracers. Thus, it seems that the population of 5-HT 2A Rs with high-affinity for agonists, that represents the active receptor conformational state, would be increased in schizophrenia whereas the total 5-HT 2A R protein density would remain unchanged. Consequently, the population of 5-HT 2A Rs with high-affinity for inverse agonists, which represents the uncoupled receptor conformational state, should be decreased in AP-free subjects. Indirect data obtained in studies with postmortem DLPFC JID: NEUPSY [m6+; 4:28 ] tissue suggest that the PET radioligand most commonly used to identify 5-HT2ARs receptors, altanserin, acts as an inverse agonist and shows responses compatible with the documented reduction of [ 18 F]altanserin binding described in PET studies of schizophrenia ( Muguruza et al., 2013 ) . Indeed, the interest in the design and further use of 5-HT 2A Rs agonist radioligands for PET studies in schizophrenia has been recognized ( L'Estrade et al., 2018 ) . Apart from selection of suitable immunological or radioligand tools for identification of 5-HT 2A Rs, confounding variables such as age, sex, PMD, and pharmacological treatment could also underlie the observed differences between postmortem evaluations of this receptor in schizophrenia. In the present work, subjects were individually matched in a way that significant differences for confounding factors between schizophrenia and control subjects were absent. It is worth mentioning that twenty-one of the 27 subjects with schizophrenia had died by suicide. Although suicide has been proposed as a confounding factor in evaluation of 5-HT 2A Rs ( Underwood et al., 2018 and references therein) , previous data in frontal cortex of suicide victims with ARTICLE IN PRESS JID: NEUPSY [m6+; 4:28 ] a variety of psychiatric disorders (see for references, Muguruza et al., 2013 Muguruza et al., , 2014 Zhao et al., 2015 ) and a recent meta-analysis have argued that suicide unlikely represents a major confounder in 5-HT 2A R binding studies ( Selvaraj et al., 2014 ) . The presence of antipsychotic treatment in schizophrenia is an essential confounding factor to be considered. Second generation antipsychotics induce changes in 5-HT 2A Rs detection through modulation of their expression as demonstrated in animal models ( González-Maeso et al., 2008 ; Kurita et al., 2012 ; Yadav et al., 2011 ) , or by blockade of the radioligand binding site due to residual presence of antipsychotics acting as 5-HT 2A R antagonists ( Dean et al., 2008a ) . Interestingly, most of the studies suggesting decreased or unchanged [ 3 H]ketanserin binding in schizophrenia have been performed in brain of AP-treated subjects (see for references, Muguruza et al., 2013 ) . Therefore, in order to discard eventual influences of antipsychotics in postmortem studies, independent and well-matched groups of AP-free and AP-treated subjects should be selected and independently analyzed. The influence of residual presence of antipsychotics competing for the radioligand binding pocket can also be overcome by using immunodetection of the 5-HT 2A R protein with selective antibodies as alternative methodology. In the present study, the immunoreactive expression of 5-HT 2A R protein is not modified in DLPFC homogenates of AP-treated subjects with schizophrenia. A similar pattern has been found in cerebellum cytosolic fractions of AP-treated schizophrenia subjects ( Eastwood et al., 2001 ) . Reevaluation of 5-HT 2A R protein expression in membrane-enriched fractions of the same subjects indicates a trend towards a reduction, associated to antipsychotic treatment, suggesting that this downregulation mainly affect the 5-HT 2A R fraction expressed in plasma membranes. This membrane P 2 fraction represents the population able to interact with G-proteins and sensitive to agonist interaction. Moreover, the analysis of HTR2A gene expression clearly confirms a reduction of HTR2A mRNA in AP-treated that was not present in AP-free subjects. This finding is consistent with previous postmortem studies performed in AP-treated populations that proposed decreased HTR2A mRNA levels in schizophrenia ( Burnet et al., 1996 ; Hernandez and Sokolov, 2000 ; López-Figueroa et al., 2004 ) . In order to confirm these effects of antipsychotic treatment on mRNA and protein expression, long-term administration of haloperidol and clozapine, which display low and high affinity for 5-HT 2A R, respectively, was performed in rats. The results show a reduction in Htr2a gene expression and in 5-HT 2A R protein immunoreactivity in membrane-enriched preparations induced by clozapine but not by haloperidol treatment. In contrast, no changes in 5-HT 2A R protein immunodetection in cortical total homogenates are observed. Moreover, radioligand binding assays in membrane fractions of the same animals demonstrate that chronic clozapine decreases [ 3 H]ketanserin binding, which mimics previous results in DLPFC from AP-treated subjects ( Muguruza et al., 2013 ) . All these findings make the overactive G αi1 -protein stimulation by ( ±)DOI an improbable consequence of longterm exposition of both AP-free and AP-treated subjects to antipsychotic drugs and point to an intrinsic alteration in schizophrenia. Globally considered, the present and previous data indicate that up-regulation of the agonist-sensitive functional 5-HT 2A R conformation in schizophrenia before treatment is counterbalanced through a decreased receptor synthesis and cell membrane protein expression induced by atypical antipsychotics. The expression of 5-HT 2A R in the cytosolic fraction of human brain homogenates is higher than in plasma membranes, a fact that induces greater experimental variability ( Eastwood et al., 2001 ) . However, although representing the minor population, 5-HT 2A R membrane fraction probably represents the population accessible to the neurotransmitter and, consequently, the most sensitive for functional coupling to G-proteins following interaction with agonists ( Bhatnagar et al., 2001 ) . The relevance that this reversion mechanism of the enhanced 5-HT 2A R function in schizophrenia plays on the therapeutic activity of atypical antipsychotics is unknown.
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The present results provide evidence of a 5-HT 2A Rs coupling to different G α -proteins in human DLPFC membranes when stimulated by the agonist ( ±)DOI, in concordance with the existence of functional selectivity or biased agonism through this receptor. In animals, activation of inhibitory G αi/o -proteins by ( ±)DOI and other LSD-like agonist drugs is considered a fingerprint of hallucinogenic properties mediated by 5-HT 2A Rs ( González-Maeso et al., 2007 ) . The enhanced ( ±)DOI-mediated 5-HT 2A R stimulation by ( ±)DOI in schizophrenia involves signaling through inhibitory G αi1 -but not G αq/11 -proteins, indicating that the functional hyperactivity of 5-HT 2A Rs is selectively exerted on hallucinogenic signal transduction pathways of this receptor. Whether other non-canonical 5-HT 2A R pathways involving G-protein dependent and independent pathways ( Roth, 2011 ) are also altered in schizophrenia remains to be studied. The drug ( ±)DOI represents a 5-HT 2A/C R agonist ( Knight et al., 2004 ) that promotes psychotic-like behaviors through 5-HT 2A Rs ( González-Maeso et al., 2003 ; Halberstadt and Geyer, 2013 ; Moreno et al., 2013 ) and disorganizes electrophysiological network activity of prefrontal cortex ( Celada et al., 2008 ) . The blockade of ( ±)DOI stimulation by the selective 5-HT 2A R antagonist ketanserin ( Knight et al., 2004 ) and the absence of this stimulation in 5-HT 2A R KO mice discard the implication of 5-HT 2C Rs in the observed effects of ( ±)DOI. The apparent scarce 5-7% increase of G αi1 -protein activation by 5-HT 2A Rs in schizophrenia is not particularly surprising, since functional response in [ 35 S]GTP γ S binding assays are known to be highly dependent on experimental conditions to detect GDP/GTP exchange. Along the same line, the possibility that this limited increase of G αi1 -protein stimulation by ( ±)DOI could represent a selective dysfunction of some DLPFC neuron subtypes, generating a dilution effect, is an alternative explanation that deserves further investigation.
In conclusion, an overactive 5-HT 2A R signal trafficking through G αi1 -proteins in DLPFC of subjects with schizophrenia that would predispose to psychotic symptoms has been found. In this context, schizophrenic patients and relatives have been described as more susceptible to psychotic responses induced by the hallucinogenic 5-HT 2A R agonist LSD ( Anastasopoulos and Photiades, 1962 ; Hoch et al., 1952 ) . Based on the present findings, it is tempting to speculate that drugs with 5-HT 2A R functional selective properties as antagonists or inverse agonists in G αi1 -protein signaling pathways could represent better pharmacological tools for JID: NEUPSY [m6+; 4:28 ] the treatment of schizophrenia than non-selective 5-HT 2A R antagonists.
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